{"id":"placebo-of-risperidone-ism","safety":{"commonSideEffects":[]},"_chembl":{"chemblId":"CHEMBL85","moleculeType":"Small molecule","molecularWeight":"410.49"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"As a placebo, this formulation contains no active pharmaceutical ingredient and serves as a control arm in Phase 3 trials. Risperidone ISM itself is a dopamine D2 and serotonin 5-HT2A receptor antagonist delivered via long-acting intramuscular injection, but the placebo version is inert and used to establish efficacy and safety of the active drug through blinded comparison.","oneSentence":"This is a placebo control formulation used in clinical trials to compare against the active Risperidone ISM (intramuscular sustained-release) antipsychotic.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:51:35.469Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Control arm in Phase 3 trials for schizophrenia or other psychotic disorders (specific indication depends on the active Risperidone ISM trial)"}]},"trialDetails":[{"nctId":"NCT03870880","phase":"PHASE3","title":"Study to Evaluate the Efficacy and Safety of Risperidone ISM® in Patients With Acute Schizophrenia: Open Label Extension","status":"COMPLETED","sponsor":"Rovi Pharmaceuticals Laboratories","startDate":"2017-08-25","conditions":"Schizophrenia","enrollment":215},{"nctId":"NCT03160521","phase":"PHASE3","title":"Study to Evaluate the Efficacy and Safety of Risperidone in Situ Microparticle (ISM)® in Patients With Acute Schizophrenia","status":"COMPLETED","sponsor":"Rovi Pharmaceuticals Laboratories","startDate":"2017-06-02","conditions":"Acute Schizophrenia","enrollment":438}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":5,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["PLACEBO"],"phase":"phase_3","status":"active","brandName":"Placebo of Risperidone ISM","genericName":"Placebo of Risperidone ISM","companyName":"Rovi Pharmaceuticals Laboratories","companyId":"rovi-pharmaceuticals-laboratories","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This is a placebo control formulation used in clinical trials to compare against the active Risperidone ISM (intramuscular sustained-release) antipsychotic. Used for Control arm in Phase 3 trials for schizophrenia or other psychotic disorders (specific indication depends on the active Risperidone ISM trial).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":false,"trials":true,"score":3}}